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Abstract: Mycobacterium tuberculosis (Mtb) DprE1, an
essential isomerase for the biosynthesis of the mycobacterial
cell wall, is a validated target for tuberculosis (TB) drug
development. Here we report the X-ray crystal structures of
DprE1 and the DprE1 resistant mutant (Y314C) in complexes
with TCA1 derivatives to elucidate the molecular basis of their
inhibitory activities and an unconventional resistance mecha-
nism, which enabled us to optimize the potency of the analogs.
The selected lead compound showed excellent in vitro and
in vivo activities, and low risk of toxicity profile except for the
inhibition of CYP2C9. A crystal structure of CYP2C9 in
complex with a TCA1 analog revealed the similar interaction
patterns to the DprE1–TCA1 complex. Guided by the
structures, an optimized molecule was generated with differ-
ential inhibitory activities against DprE1 and CYP2C9, which
provides insights for development of a clinical candidate to
treat TB.
Mtb Decaprenylphosphoryl-b-d-ribofuranose 2-oxidase
(DprE1) is a flavin adenine dinucleotide (FAD)-dependent
enzyme, which together with decaprenylphosphoryl-d-2-
ketoerythropentose reductase (DprE2), converts decaprenyl-
phosphoryl-beta-d-ribose (DPR) to decaprenylphosphoryl-
beta-d-arabinofuranose (DPA), an essential cell wall compo-
nent.[1] Conditional knockdown studies showed that loss of
dprE1 results in a strong bactericidal effect in vitro.[2] Multi-
ple covalent[3] and non-covalent[4]DprE1 inhibitors have been
identified and showed in vitro and in vivo activities against
Mtb, further validating DprE1 as an attractive anti-tuber-
culosis (TB) drug target.[5]
We previously reported the identification of TCA1 from
a cell-based phenotypic screen, and demonstrated it is
a DprE1 inhibitor.[6] Since then we have generated new
derivatives of TCA1 to improve its in vitro potency, PK
properties, and in vivo efficacy. When analyzing toxicity
profiles, we noticed that many TCA1 analogs show inhibition
of CYP2C9, one of six major cytochrome P450 enzymes which
determine the clearance of 75% of marketed drugs. There-
fore, inhibition of P450 enzymes such as CYP2C9 can
potentially lead to drug–drug interactions, which may cause
serious issues for combinatory drug regimen for TB treat-
ment.[7]
Here we report the X-ray crystal structures of WTDprE1,
a TCA1-resistant DprE1 mutant, and CYP2C9 in complex
with TCA1 analogs. Along with structure activity relationship
studies, the mechanism of resistance by the mutant DprE1
enzyme and the tight correlation between DprE1 and
CYP2C9 inhibition was elucidated. We further generated
analogs with excellent in vitro and in vivo activities against
Mtb, and selectively targeting DprE1 over CYP2C9.
In the DprE1–TCA1 structure, TCA1 showed a planar
conformation and tight fit in the DprE1 active site. The
benzothiazole core is oriented parallel to the FAD isoallox-
azine ring and the thiophene carboxamide resides in small
hydrophobic pocket. Besides substantial hydrophobic inter-
actions, multiple hydrogen bonding interactions are formed
between TCA1 and residues Lys418, His132, and Ser228
(Figure S1 in the Supporting Information, SI). Guided by the
structure, our medicinal chemistry effort focused on the
benzothiazole core (red), thiophene carboxamide (green) and
the acylcarbamate (blue) of TCA1 (Figure 1).
The Gln334 amide group and the Tyr60 hydroxy group are
only 3.7c away from C4 and C5 of the TCA1 benzothiazole
ring, respectively, which make them two potential H-bond
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donors if H-bond acceptors are introduced at these positions
(Figure 1 and Figure S1). Indeed, the introduction of nitrogen
to the benzothiazole ring (TCA007) improved the IC50 by 8-
fold (5: 2 nm) compared to TCA1 (48: 14 nm) (Figure 1,
Table 1, SI methods and Figure S2–S4).
The thiophene ring is located in a hydrophobic pocket
formed by Gly133, Lys367, Phe369 and Asn385 and accepts
a H-bond from His132 Ne2 (3.2c). Replacement of thio-
phene with other heterocycles or adding bulky substitutions
resulted in reduced activity against Mtb (data not shown).
Only a fluoro substituent on the thiophene afforded an analog
(TCA481) that is 5-fold more potent than TCA1 based on
MIC (Figure 1 and Table 1). To better understand the basis of
the activity increase, we solved the crystal structure of DprE1
in complex with TCA481 (Table S1). The structure reveals
that the fluoro group forms a H-bond with Asn385 Nd2
(3.4c). The fluorine is accommodated in the pocket with
stronger hydrophobic interactions with residues Phe369,
His132, and Lys367 than TCA1 (Figure 2B and Figure S1).
Modification of the carbamate group was carried out;
however, most of the analogs such as amides and esters are
not active, demonstrating the importance of hydrogen bond-
ing between Ser228 and the carbamate group (3.0 to 3.5c)
(Figure 2C and Figure S1). When replacing the carbamate
with various heterocycles, only TCA020 with pyrimidine
showed moderate activity (MIC= 2.5 mm, IC50= 370:
133 nm) (Figure 1 and Table 1). To help optimizing the
pyrimidyl substituent, we crystallized DprE1 in complex
with TCA020 (SI methods). The DprE1–TCA1 structure
revealed that the two nitrogen atoms of the pyrimidine ring
occupy the positions of the two oxygens of the carbamate
group as H-bond acceptors. Based on these structural insights,
we introduced a methyl group at 4-position of the pyrimidine
to gain a hydrophobic interaction with W230 (TCA787),
which has similar activity to TCA1 (Figure 1 and Table 1).
Y314 resides close to the carbamate moiety and it was
previously found that a spontaneous TCA1 resistant mutant
harbors a Y314C mutation.[6] We measured the inhibitory
activities of TCA1 and its analogs against DprE1 and the
Y314C variant and observed 5- to 40-fold shift on IC50 values
under the same assay condition, which is consistent with the
MIC shift between the wildtype (WT) and the mutant strain
(Table 1). These data support the notion that growth inhib-
ition of Mtb by the TCA1 series of inhibitors is via DprE1
inhibition. We also generated a Y314A mutant and it is
sensitive to TCA1 inhibition, suggesting that the side chain of
Y314 does not directly contribute to TCA1 binding
(Table S2). To elucidate the molecular basis of the resistance
mechanism, the structure of DprE1 Y314C bound with TCA1
was determined to 2.2c (Figure 2D, Figure S1 and Table S1).
Figure 1. SAR optimization strategy for TCA1 analogs. Benzothiazole
core (red), thiophene carboxamide (green) and acylcarbamate (blue).
Table 1: Correlation between inhibition on DprE1 WT and mutant
enzyme activity and cellular potency by TCA1 and analogs (mm).[4d]
TCA1
analogs
IC50 DprE1
WT[a]
IC50 DprE1
Y321C[a]
MIC WT MIC
Y314C
TCA1 0.048:0.014 0.24:0.052 0.23:0.012 5.4:0.32
TCA007 0.0053:0.18 0.13:0.021 0.089:0.0066 2.4:0.34
TCA481 ND[b] ND[b] 0.046:0.0025 1.4:0.086
TCA020 0.37:0.13 >10 2.5:0.48 17:1.1
TCA787 0.096:0.038 1.8:0.54 0.44:0.12 14:1.4
[a] All in vitro assays were performed using M. smegmatis DprE1 which
shows 83% sequence identity with Mtb DprE1. M. smegmatis Y321C
corresponds to Y314C inMtb. [b] IC50 of TCA481 was not determined due
to its low solubility under the assay condition.
Figure 2. Non-covalent interactions of TCA inhibitors with DprE1.
A) Inhibitor TCA020 (pink) with non-covalent interactions indicated in
dashed lines (magenta). The unbiased Fo@Fc density map (contoured
at 2.5s) was calculated with model phases prior to incorporation of
the ligand in the structural model. Protein residues are shown in gray
sticks, FAD in yellow sticks. B,C) Superposition of TCA1 with the
inhibitors TCA481 and TCA020, respectively. Dashed lines in cyan
indicate new or shortened non-covalent interactions compared to the
TCA1:wt-DprE1 complex (see Figure S1 for contact distances). Protein
side chains in green indicate amino acids that—in TCA1:wt-DprE1—
fall outside the 4 b contact radius. D) The flipped orientation of TCA1
(cyan) in the DprE1–Y314C active site.
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Although the overall fold of the mutant enzyme is identical to
wildtype, consequential structural changes in the active site of
DprE1 were evident. The most striking difference between
the WT and mutant DprE1 complexes is the 1808 flipped
orientation of the boomerang-shaped ligand in the active site
(Figure S1 and Figure S5). The alternative orientation of the
ligand can be linked to the effects of cysteine 314 substitution
on the orientation of Lys134, which positions the e-ammoni-
um group in the void created by substituting the tyrosyl ring
with a thiol. The reorientation of Lys134 is driven by
formation of a strong H-bond (2.75c) between its e-
ammonium and the thiol of Cys314 and results in a noticeable
shape change of the active site around Lys134. Consequently,
the acylcarbamate keto-oxygen in the original orientation
would clash with the alkyl moiety of Lys134 (with the shortest
distance at 2.7c), which likely weakens the binding of TCA1
(Figure S5).
Due to its superior activity againstMtb and improved PK
properties, TCA007 was selected as a lead compound for
further investigation. We evaluated the efficacy of TCA007
againstMtb Erdman in acute and chronic BALB/c mouse low
dose aerosol infection models.[8] After treatment for 3 weeks
during the acute phase of infection with TCA007 at a dose of
50 mgkg@1 and 100 mgkg@1 body weight, a dose-dependent
in vivo efficacy was observed with reduction of bacterial load
in lung by 1.7 and 2.3 log10 CFU, respectively (Figure 3A and
SI methods). This excellent in vivo bactericidal activity is
comparable to the first-line drug rifampin. Following 4 weeks
of treatment during the chronic phase of infection, TCA007 at
200 mgkg@1 achieved a reduction of > 1.7 log10 CFU in mouse
lungs (Figure 3B).
A typical treatment of TB lasts for more than six months,
and therefore, the safety profile of anti-TB drugs is of great
importance. TCA007 is not cytotoxic against Vero and
HepG2 cell lines at up to a concentration of 100 mm.
TCA007 does not inhibit hERG potassium channel in
a patch-clamp assay (IC50> 30 mm), suggesting a low risk of
cardiotoxicity. In addition, we observed no genetic toxicity in
a mini-Ames mutagenicity test. TCA007 showed no inhibition
of four major CYPs, 1A2, 3A4, 2D6, 2C19, but a strong
inhibitory effect for CYP2C9 (SI methods).
The potent inhibition of P450 2C9 could reflect oxygen-
ation of thiophene moiety of TCA analogs to an electrophilic
S-oxide or epoxide[9] that reacts with the enzyme to form an
irreversible inhibitor as seen for tienilic acid.[10] However, the
inhibition of 2C9 by TCA analogs was not time dependent
indicating a reversible mode (Figure S6). To better under-
stand the interactions of TCA007 with 2C9, the structure of
the complex was determined by X-ray crystallography to
2.0 c resolution[11] (PDB: 5W0C) (SI methods, Table S3 and
Figure S7). Similar to the binding of TCA1 to DprE1, the
thiophene group of TCA007 binds in a hydrophobic pocket of
the 2C9 substrate binding cavity that is far from the iron of the
heme cofactor where the reactive oxidant is formed, thus
preventing oxygenation of the thiophene moiety. The pocket
is formed by the inner surface of helix B’ and adjacent
residues (Figure 4A) and hydrophobic residues on helix F
Figure 3. In vivo efficacy study. A) Efficacy of TCA007 in a mouse acute
model of established TB. B) Efficacy of TCA007 in a mouse chronic
model of established TB. The in vivo dose (mgkg@1) of each com-
pound is shown in parentheses.
Figure 4. Crystal structure of CYP2C9 with TCA007. A) Key interactions
exhibited by TCA007 (violet carbons) in the CYP2C9 active site
(PDB:5W0C). Amino acid side-chains that contact TCA007 are ren-
dered as sticks. The red spheres are water molecules, and the dashed
lines depict H-bonds. B,C) Modeling TCA711 (cyan) in the CYP2C9
structure (overlap with TCA007 in violet) (B) and DprE1 structure
(overlap with TCA1 in megenta) (C). D) SAR optimization strategy for
TCA1.
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across from B’ and helix G above TCA007. Mimicking the
role of DprE1 Lys418, Arg108 donates H-bonds from Ne to
the carbonyl oxygen of the thiophene carboxamide (3.0c)
and from Nh2 to the thiazole nitrogen (3.4c). The thiophene
carbonyl also accepts an H-bond from a water molecule. The
Arg108 Ne also contacts the thiophene sulfur. Arg108 plays
a critical role in recruiting negatively charged or partially
charged substrates such as diclofenac and warfarin, respec-
tively, to the substrate binding site of 2C9. Substitution of
Arg108 by alanine,[12] histidine or phenylalanine[13] leads to
a loss catalytic activity for the two substrates.
Phe100, Leu102, and Phe114 form a hydrophobic pocket
together with Phe476 where the carbamate group of TCA007
is bound (Figure 4A). In contrast to DprE1, protein H-bond
donors for the carbamate are not present in this pocket, but
the cavity is open to solvent and an ordered water molecule
donates an H-bond to the carbonyl of the acyl group. The
pyridyl nitrogen of the pyridothiozole group is oriented
toward the heme but is too distant (6.6c) for coordination to
the heme iron. Consistent with this observation, TCA007 does
not significantly alter the visible absorption spectrum of 2C9
in solution. In contrast, miconazole binds to the heme iron of
2C9 and alters the spectrum of the heme co-factor, and
competitive displacement of iron bound miconazole by
TCA007 reverts the spectrum of the miconazole complex to
that of the apo enzyme (Figure S8). This portion of the active
site is also hydrophobic, but a molecule of water is evident
2.88c from the pyridyl nitrogen of TCA007 (Figure 4A). The
water molecule is hydrogen bonded to a second water
molecule that donates a lone pair of electrons to the heme
iron and a H-bond to the backbone carbonyl of Ala297. In
general, the extensive hydrophobic interactions and hydrogen
bonding interactions with Arg108 are likely to form the basis
for the high affinity, reversible binding of TCA007 to 2C9, but
these interactions also sequester TCA007 in position that
reduces the likelihood of metabolism, which is consistent with
absent or low rates of metabolite formation or time depen-
dent inhibition.
Removal of these aforementioned heteroatoms will likely
reduce the CYP2C9 inhibition. However, it was shown that
the thiophene group and carbonyl group are also essential for
DprE1 binding. Therefore, we instead modified the ring A to
reduce CYP2C9 inhibition while gaining extra interactions in
ring B to maintain DprE1 binding (Figure 4B). Both sulfur
and nitrogen in the ring A were removed to reduce the
interaction in CYP2C9, and two nitrogens were introduced
into ring B which potentially form H-bonds with Tyr60 and
Glu334 to compensate for the reduced interaction in DprE1
(Figure 4C). The IC50 ratio (CYP2C9 over DprE1) for
TCA582 and TCA711 were 33 and 1515, respectively,
which, compared with TCA007 (ratio= 1.8), represents a sig-
nificant improvement in selectivity (Figure 4D). The model-
ing of CYP2C9 with both TCA582 and TCA711 revealed that
the carbamate group could gain favorable hydrophobic
interactions with Phe100 (3.6c), Phe114 (4.1c) and
Phe476 (3.8c). These interactions would be weakened by
an unfavorable hydrophobic interaction with Phe100 (2.9c
and 3.0c) when replacing the carbamate with pyrimidyl
substituent, which could explain the nearly eliminated
inhibition of CYP2C9 by TCA711 (IC50 of CYP2C9
> 50 um) (Figure 4D). The in vivo studies on the advanced
analog TCA711 are ongoing.
In summary, we demonstrate the mode of inhibition of
DprE1 by the thiophene scaffold via enzymatic and structural
studies. The SAR studies not only helped us to optimize the
potency of the inhibitors but revealed an unconventional
resistant mechanism of DprE1. The optimized lead com-
pound TCA007 showed excellent in vitro and in vivo activ-
ities, PK properties, and low risk of toxicity profile except for
the strong inhibition of CYP2C9. Guided by the structures of
CYP2C9 in complex with TCA1 analogs, an optimized
molecule, TCA711, was generated with differential inhibitory
activities against DprE1 and CYP2C9, which paved the road
for further development of a clinical candidate to treat TB.
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